» Articles » PMID: 11431195

Glomerular Osteopontin Expression and Macrophage Infiltration in Glomerulosclerosis of DOCA-salt Rats

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 2001 Jun 30
PMID 11431195
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Expression of the chemoattractant osteopontin (OPN) may contribute to macrophage infiltration in many types of tubulointerstitial kidney disease, but the role of OPN in chronic glomerulosclerosis is unknown. We hypothesized that glomerular OPN expression and macrophage infiltration occur in deoxycorticosterone acetate (DOCA)-salt glomerulosclerosis in rats. Uninephrectomized rats receiving DOCA pellets and 1% saline were compared with control rats. OPN mRNA was determined by Northern blot, and OPN protein was determined by Western blot. The localization of OPN was studied by in situ hybridization and double immunohistochemistry with glomerular cell markers. Macrophage infiltration was quantified by counting ED-1-positive cells, and semiquantitative glomerulosclerosis scores were obtained. In DOCA-salt rats, OPN mRNA in the kidney was increased 2-fold over control after 9 days and 3 weeks and 20-fold after 6 weeks. Tubulointerstitial OPN staining was apparent after 21 days of DOCA treatment. Glomerular OPN mRNA and protein was detected after 42 days in parietal and visceral epithelial cells, activated myofibroblasts, and occasionally mesangial cells. Progressive glomerular macrophage infiltration occurred during the development of DOCA hypertension, paralleling the degree of glomerulosclerosis. Glomeruli staining positive for osteopontin contained more macrophages (18.4 +/- 3.4 per cross-section) than osteopontin-negative glomeruli (3.6 +/- 0.5; P < 0.05). Glomerular OPN expression occurs in chronic hypertensive glomerulosclerosis and is associated with macrophage infiltration. The data suggest a role for OPN as a chemoattractant in hypertensive glomerulosclerosis.

Citing Articles

Roles of macrophages in lupus nephritis.

Cheng Y, Liu L, Ye Y, He Y, Hu W, Ke H Front Pharmacol. 2024; 15:1477708.

PMID: 39611168 PMC: 11602334. DOI: 10.3389/fphar.2024.1477708.


A new immune disease: systemic hypertension.

Copur S, Peltek I, Mutlu A, Tanriover C, Kanbay M Clin Kidney J. 2023; 16(9):1403-1419.

PMID: 37664577 PMC: 10469084. DOI: 10.1093/ckj/sfad059.


Proficient Novel Biomarkers Guide Early Detection of Acute Kidney Injury: A Review.

Jana S, Mitra P, Roy S Diseases. 2023; 11(1).

PMID: 36648873 PMC: 9844481. DOI: 10.3390/diseases11010008.


O-Linked β--Acetylglucosamine Modification: Linking Hypertension and the Immune System.

Dos Passos Junior R, Bomfim G, Giachini F, Tostes R, Lima V Front Immunol. 2022; 13:852115.

PMID: 35371030 PMC: 8967968. DOI: 10.3389/fimmu.2022.852115.


Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome.

Ning L, Suleiman H, Miner J Am J Physiol Renal Physiol. 2021; 321(1):F12-F25.

PMID: 34029143 PMC: 8321802. DOI: 10.1152/ajprenal.00035.2021.